<div>A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus</div><div>Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with</div><div>Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung</div><div>Cancer with KRAS G12C Mutation (KRYSTAL-4)</div>

BMS CA239-0004 (KRYSTAL-4)

Comprehensive Cancer Center Mainfranken

Lungentumoren

Nicht-kleinzelliges Bronchialkarzinom (NSCLC)

KRAS

ras-Gen

KRAS-G12C

PD-1 (Programmed cell death protein 1)

PD-L1

Phase III

Herr Dr. Horst-Dieter Hummel

Frau Dr. Maria-Elisabeth Goebeler

Herr Dr. Cyrus Sayehli

Interdisziplinäres Studienzentrum mit Early Clinical Trial Unit

Universitätsklinikum Würzburg

Therapeutisch